Understanding the Market | KEYMED BIO-B rises over 7% as Goldman Sachs states that Siponimod is expected to lay the foundation for the company's valuation
I'm PortAI, I can summarize articles.
KEYMED BIO-B's stock price rose over 7%, with an increase of 7.14% as of the time of writing, reported at HKD 64.55, with a trading volume of HKD 281 million. Goldman Sachs has given KEYMED BIO-B a "Buy" rating, with a target price of HKD 92.67, believing that its first commercialized product, Stapokibart, will lay the valuation foundation for the company, with peak sales expected to reach RMB 5 billion by 2035. The CM512 drug is also viewed positively, with global sales expected to reach USD 3.3 billion by 2035
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments